Sorry, I was referring to the fact that Deb025 seeks to disrupt the interaction between CypA and NS5A (see link) whereas EDP-239 seeks to inhibit the non-structural 5A (NS5A) protein encoded by the hepatitis C virus. In either case it appears that the two drugs are approaching the same target via two different pathways. Is this correct?
Please excuse my limited understanding here, but is it likely that NVS interest in Enanta is a combination drug with Deb025? Would it be unusual for a combination drug to seek to disrupt what seems like a pretty focused target (NS5A)? Again, just trying to gain insights where NVS might be headed.
Market Data 
Markets 
AI
